{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:30:17Z","timestamp":1794717017486,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Austrian Federal Ministry for Digital and Economic Affairs"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the therapeutic response to brolucizumab and aflibercept by deep learning\/OCT-based analysis of macular fluid volumes in neovascular age-related macular degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this post-hoc analysis of two phase III, randomised, multi-centre studies (HAWK\/HARRIER), 1078 and 739 treatment-naive eyes receiving brolucizumab or aflibercept according to protocol-specified criteria in HAWK and HARRIER, respectively, were included. Macular fluid on 41,840 OCT scans was localised and quantified using a validated deep learning-based algorithm. Volumes of intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED) for all central macular areas (1, 3 and 6\u2009mm) in nanolitres (nL) and best corrected visual acuity (BCVA) change in ETDRS letters were associated using mixed models for repeated measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline IRF volumes decreased by &gt;92% following the first intravitreal injection and consistently remained low during follow-up. Baseline SRF volumes decreased by &gt;74% following the first injection, while PED volume resolved by 68\u201379% of its baseline volume. Resolution of SRF and PED was dependent on the substance and regimen used. Larger residual post-loading IRF, SRF and PED volumes were all independently associated with progressive vision loss during maintenance, where the differences in mean BCVA change between high and low fluid volume subgroups for IRF, SRF and PED were 3.4 letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), 1.7 letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and 2.5 letters (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Deep-learning methods allow an accurate assessment of substance and regimen efficacy. Irrespectively, all fluid compartments were found to be important markers of disease activity and were relevant for visual outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-022-02077-4","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T05:06:04Z","timestamp":1651813564000},"page":"1160-1169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7788-7311","authenticated-orcid":false,"given":"Ursula","family":"Schmidt-Erfurth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zufar","family":"Mulyukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8940-8130","authenticated-orcid":false,"given":"Bianca S.","family":"Gerendas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7661-4015","authenticated-orcid":false,"given":"Gregor S.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lorand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Weissgerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-0894","authenticated-orcid":false,"given":"Hrvoje","family":"Bogunovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"2077_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367.","journal-title":"Br J Ophthalmol."},{"key":"2077_CR2","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.2147\/OPTH.S275977","volume":"14","author":"H Mehta","year":"2020","unstructured":"Mehta H, Kim LN, Mathis T, Zalmay P, Ghanchi F, Amoaku WM, et al. Trends in real-world neovascular AMD treatment outcomes in the UK. Clin Ophthalmol. 2020;14:3331\u201342.","journal-title":"Clin Ophthalmol."},{"key":"2077_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","volume":"4","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A. SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States. Ophthalmol Retin. 2020;4:122\u201333.","journal-title":"Ophthalmol Retin"},{"key":"2077_CR4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ophtha.2020.02.027","volume":"127","author":"S Kiss","year":"2020","unstructured":"Kiss S, Campbell J, Almony A, Shih V, Serbin M, LaPrise A, et al. Management and Outcomes for Neovascular Age-Related Macular Degeneration: analysis of United States electronic health records. Ophthalmol. 2020;127:1179\u201388.","journal-title":"Ophthalmol"},{"key":"2077_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","volume":"127","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, et al. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmol. 2020;127:963\u201376.","journal-title":"Ophthalmol"},{"key":"2077_CR6","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","volume":"124","author":"PU Dugel","year":"2017","unstructured":"Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, et al. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: a randomized trial. Ophthalmol. 2017;124:1296\u2013304.","journal-title":"Ophthalmol"},{"key":"2077_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmol. 2020;127:72\u201384.","journal-title":"Ophthalmol"},{"key":"2077_CR8","unstructured":"Novartis. Novartis receives FDA approval for Beovu\u00ae, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept. 2019. https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept."},{"key":"2077_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1\u201324.","journal-title":"Prog Retin Eye Res."},{"key":"2077_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","volume":"125","author":"T Schlegl","year":"2018","unstructured":"Schlegl T, Waldstein SM, Bogunovic H, Endstra\u00dfer F, Sadeghipour A, Philip AM, et al. Fully Automated Detection and Quantification of Macular Fluid in OCT Using Deep Learning. Ophthalmol. 2018;125:549\u201358.","journal-title":"Ophthalmol"},{"key":"2077_CR11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha.2020.03.010","volume":"127","author":"UM Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth UM, Vogl W, Jampol LM, Bogunovi\u0107 H. Application of Automated Quantification of Fluid Volumes to Anti\u2013VEGF Therapy of Neovascular Age-Related Macular Degeneration. Ophthalmol. 2020;127:1211\u20139.","journal-title":"Ophthalmol"},{"key":"2077_CR12","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/jamaophthalmol.2020.2457","volume":"138","author":"PK Roberts","year":"2020","unstructured":"Roberts PK, Vogl W-D, Gerendas BS, Glassman AR, Bogunovic H, Jampol LM, et al. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020;138:945\u201353.","journal-title":"JAMA Ophthalmol"},{"key":"2077_CR13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1109\/TMI.2009.2016958","volume":"28","author":"MK Garvin","year":"2009","unstructured":"Garvin MK, Abr\u00e0moff MD, Wu X, Russell SR, Burns TL, Sonka M. Automated 3-D intraretinal layer segmentation of macular spectral-domain optical coherence tomography images. IEEE Trans Med Imaging. 2009;28:1436\u201347.","journal-title":"IEEE Trans Med Imaging."},{"key":"2077_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1109\/TPAMI.2006.19","volume":"28","author":"K Li","year":"2006","unstructured":"Li K, Wu X, Chen DZ, Sonka M. Optimal Surface Segmentation in Volumetric Images-A Graph-Theoretic Approach. IEEE Trans Pattern Anal Mach Intell. 2006;28:119\u201334.","journal-title":"IEEE Trans Pattern Anal Mach Intell."},{"key":"2077_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","volume":"122","author":"UM Schmidt-Erfurth","year":"2015","unstructured":"Schmidt-Erfurth UM, Waldstein SM, Deak G-G, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmol. 2015;122:822\u201332.","journal-title":"Ophthalmol"},{"key":"2077_CR16","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","volume":"121","author":"C Simader","year":"2014","unstructured":"Simader C, Ritter M, Bolz M, De\u00e1k GG, Mayr-Sponer U, Golbaz I, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmol. 2014;121:1237\u201345.","journal-title":"Ophthalmol"},{"key":"2077_CR17","doi-asserted-by":"publisher","first-page":"9054","DOI":"10.1074\/jbc.M109.072876","volume":"285","author":"L Borras","year":"2010","unstructured":"Borras L, Gunde T, Tietz J, Bauer U, Hulmann-Cottier V, Grimshaw JPA, et al. Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem. 2010;285:9054\u201366.","journal-title":"J Biol Chem."},{"key":"2077_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","volume":"123","author":"FG Holz","year":"2016","unstructured":"Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, et al. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: a randomized controlled study. Ophthalmol. 2016;123:1080\u20139.","journal-title":"Ophthalmol"},{"key":"2077_CR19","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A, Pillai N, Wilkes E, Benyamini G, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye 2021;35:2983\u201390.","journal-title":"Eye"},{"key":"2077_CR20","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1097\/IAE.0000000000003180","volume":"41","author":"C Grechenig","year":"2021","unstructured":"Grechenig C, Reiter GS, Riedl S, Arnold J, Guymer R, Gerendas BS, et al. Impact of residual subretinal fluid volumes on treatment outcomes in a subretinal fluid\u2013tolerant treat-and-extend regimen. Retina. 2021;41:2221\u20138.","journal-title":"Retina."},{"key":"2077_CR21","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.ophtha.2014.04.020","volume":"121","author":"FA Folgar","year":"2014","unstructured":"Folgar FA, Jaffe GJ, Ying G-S, Maguire MG, Toth CA. Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmol. 2014;121:1956\u201365.","journal-title":"Ophthalmol"},{"key":"2077_CR22","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/IAE.0000000000000483","volume":"35","author":"CA Toth","year":"2015","unstructured":"Toth CA, Decroos FC, Ying G-S, Stinnett SS, Heydary CS, Burns R, et al. Identification of fluid on optical coherence tomography by treating ophthalmologists versus a reading center in the comparison of age-related macular degeneration treatments trials. Retina 2015;35:1303\u201314.","journal-title":"Retina"},{"key":"2077_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ophtha.2020.06.038","volume":"128","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Clemons TE, Domalpally A, Elman MJ, Havilio M, Agr\u00f3n E, et al. Retinal Specialist versus Artificial Intelligence Detection of Retinal Fluid from OCT. Ophthalmol. 2021;128:100\u20139.","journal-title":"Ophthalmol"},{"key":"2077_CR24","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","volume":"122","author":"AS Willoughby","year":"2015","unstructured":"Willoughby AS, Ying G-S, Toth CA, Maguire MG, Burns RE, Grunwald JE, et al. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmol. 2015;122:1846\u201353.e5.","journal-title":"Ophthalmol"},{"key":"2077_CR25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/IAE.0000000000003023","volume":"41","author":"GS Reiter","year":"2021","unstructured":"Reiter GS, Grechenig C, Vogl W-D, Guymer RH, Arnold JJ, Bogunovic H, et al. Analysis of fluid volume and its impact on visual acuity in the fluid study as quantified with deep learning. Retina 2021;41:1318\u201328.","journal-title":"Retina"},{"key":"2077_CR26","doi-asserted-by":"crossref","unstructured":"Pawloff M, Bogunovi\u0107 H, Michl M, Riedl S, Schmidt-Erfurth UM. Systematic correlation of central subfield thickness with retinal fluid volumes quantified by deep learning in the major exudative macular diseases. Retina. 2022;42:831\u201341.","DOI":"10.1097\/IAE.0000000000003385"},{"key":"2077_CR27","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41591-018-0107-6","volume":"24","author":"J De Fauw","year":"2018","unstructured":"De Fauw J, Ledsam JR, Romera-Paredes B, Nikolov S, Tomasev N, Blackwell S, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med. 2018;24:1342\u201350.","journal-title":"Nat Med."},{"key":"2077_CR28","doi-asserted-by":"crossref","unstructured":"Michl M, Fabianska M, Seeb\u00f6ck P, Sadeghipour A, Haj Najeeb B, Bogunovic H, et al. Automated quantification of macular fluid in retinal diseases and their response to anti-VEGF therapy. Br J Ophthalmol. 2020: bjophthalmol-2020-317416.","DOI":"10.1136\/bjophthalmol-2020-317416"},{"key":"2077_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER. Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmol. 2021;128:89\u201399.","journal-title":"Ophthalmol"},{"key":"2077_CR30","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, et al. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. Ophthalmol. 2016;123:1521\u20139.","journal-title":"Ophthalmol"},{"key":"2077_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe GJ, Ying G-S, Toth CA, Daniel E, Grunwald JE, Martin DF, et al. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmol. 2019;126:252\u201360.","journal-title":"Ophthalmol"},{"key":"2077_CR32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","volume":"138","author":"RN Evans","year":"2020","unstructured":"Evans RN, Reeves BC, Maguire MG, Martin DF, Muldrew A, Peto T, et al. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti\u2013Vascular Endothelial Growth Factor Agents. JAMA Ophthalmol. 2020;138:1043.","journal-title":"JAMA Ophthalmol"},{"key":"2077_CR33","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/jpm11101024","volume":"11","author":"TYY Lai","year":"2021","unstructured":"Lai TYY, Lai RYK. Association between Retinal Thickness Variability and Visual Acuity Outcome during Maintenance Therapy Using Intravitreal Anti-Vascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration. J Pers Med. 2021;11:1024.","journal-title":"J Pers Med."},{"key":"2077_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","volume":"123","author":"S Sharma","year":"2016","unstructured":"Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying G-S, et al. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmol. 2016;123:865\u201375.","journal-title":"Ophthalmol"},{"key":"2077_CR35","unstructured":"Riedl S, Vogl W-D, Waldstein SM, Schmidt-Erfurth UM, Bogunovi\u0107 H. Correlation of functional loss and recovery with fluid volumes quantified by deep learning during therapy of neovascular AMD. under peer Rev."},{"key":"2077_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/OPTH.S125676","volume":"11","author":"K Spooner","year":"2017","unstructured":"Spooner K, Hong T, Wijeyakumar W, Chang AA. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clin Ophthalmol. 2017;11:161\u201377.","journal-title":"Clin Ophthalmol."},{"key":"2077_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/IAE.0000000000001947","volume":"39","author":"K Kim","year":"2019","unstructured":"Kim K, Kim ES, Kim Y, Yang JH, Yu S-Y, Kwak HW. Outcome of intravitreal aflibercept for refractory pigment epithelial detachment with or without subretinal fluid and secondary to age-related macular degeneration. Retina 2019;39:303\u201313.","journal-title":"Retina"},{"key":"2077_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2018.07.004","volume":"67","author":"U Schmidt-Erfurth","year":"2018","unstructured":"Schmidt-Erfurth U, Sadeghipour A, Gerendas BS, Waldstein SM, Bogunovi\u0107 H. Artificial intelligence in retina. Prog Retin Eye Res. 2018;67:1\u201329.","journal-title":"Prog Retin Eye Res."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02077-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02077-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02077-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T22:54:22Z","timestamp":1700520862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02077-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02077-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"assertion":[{"value":"26 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"US-E: Scientific consultancy to Novartis, Genentech, Roche, Kodiak, Heidelberg Engineering, and RetInSight. ZM, DL, GW: Employees of Novartis. BSG: Scientific consultancy to Novartis and Roche. GSR: Financial support (grants) from RetInSight. HB: Financial support (grants) from Heidelberg Engineering and Apellis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}